|
rdf:type |
|
|
lifeskim:mentions |
umls-concept:C0009429,
umls-concept:C0011777,
umls-concept:C0023610,
umls-concept:C0205269,
umls-concept:C0262950,
umls-concept:C0376358,
umls-concept:C0449445,
umls-concept:C0556895,
umls-concept:C0732165,
umls-concept:C1314939,
umls-concept:C1515985,
umls-concept:C1516213
|
|
pubmed:issue |
7
|
|
pubmed:dateCreated |
2006-6-21
|
|
pubmed:abstractText |
The development of resistance to anticancer therapies is a major hurdle in preventing long-lasting clinical responses to conventional therapies in hormone-refractory prostate cancer. Herein, the molecular evidence documenting that bone metastasis microenvironment survival factors (mainly the paracrine growth hormone-independent, urokinase-type plasminogen activator-mediated increase of IGF-1 and the endocrine production of growth hormone-dependent IGF-1, mainly liver-derived IGF-1 production) produce an epigenetic form of prostate cancer cells that are resistant to proapoptotic therapies is reviewed. Consequently, the authors present the conceptual framework of a novel antibone microenvironment survival factor, mainly an anti-IGF-1 hormonal manipulation for androgen ablation refractory prostate cancer (a combination of conventional androgen ablation therapy [luteinising hormone-releasing hormone agonist-A or orchiectomy]) with dexamethasone plus somatostatin analogue, which yielded durable objective responses and major improvement of bone pain and performance status in stage D3 prostate cancer patients.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
http://linkedlifedata.com/resource/pubmed/chemical/Androgen Antagonists,
http://linkedlifedata.com/resource/pubmed/chemical/Androgens,
http://linkedlifedata.com/resource/pubmed/chemical/Antineoplastic Agents, Hormonal,
http://linkedlifedata.com/resource/pubmed/chemical/Dexamethasone,
http://linkedlifedata.com/resource/pubmed/chemical/Estramustine,
http://linkedlifedata.com/resource/pubmed/chemical/Etoposide,
http://linkedlifedata.com/resource/pubmed/chemical/Gonadotropin-Releasing Hormone,
http://linkedlifedata.com/resource/pubmed/chemical/Growth Substances,
http://linkedlifedata.com/resource/pubmed/chemical/Leuprolide,
http://linkedlifedata.com/resource/pubmed/chemical/Neoplasm Proteins,
http://linkedlifedata.com/resource/pubmed/chemical/Peptides, Cyclic,
http://linkedlifedata.com/resource/pubmed/chemical/Receptors, Androgen,
http://linkedlifedata.com/resource/pubmed/chemical/Somatostatin,
http://linkedlifedata.com/resource/pubmed/chemical/Triptorelin Pamoate,
http://linkedlifedata.com/resource/pubmed/chemical/lanreotide
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Jul
|
|
pubmed:issn |
1744-7658
|
|
pubmed:author |
pubmed-author:BogdanosJohnJ,
pubmed-author:DimopoulosPeterP,
pubmed-author:DimopoulosTheodorosT,
pubmed-author:HalapasAntonisA,
pubmed-author:KaramanolakisDimitriosD,
pubmed-author:KatopodisHaralamposH,
pubmed-author:KoutsilierisMichaelM,
pubmed-author:LembessisPeterP,
pubmed-author:MilathianakisConstantineC,
pubmed-author:PapageorgiouEffieE,
pubmed-author:PissimissisNikosN,
pubmed-author:PitulisNeaN,
pubmed-author:SourlaAntigoneA,
pubmed-author:TentaRoxaneR
|
|
pubmed:issnType |
Electronic
|
|
pubmed:volume |
15
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
795-804
|
|
pubmed:dateRevised |
2011-11-17
|
|
pubmed:meshHeading |
pubmed-meshheading:16787142-Adenocarcinoma,
pubmed-meshheading:16787142-Androgen Antagonists,
pubmed-meshheading:16787142-Androgens,
pubmed-meshheading:16787142-Antineoplastic Agents, Hormonal,
pubmed-meshheading:16787142-Antineoplastic Combined Chemotherapy Protocols,
pubmed-meshheading:16787142-Apoptosis,
pubmed-meshheading:16787142-Bone Neoplasms,
pubmed-meshheading:16787142-Clinical Trials, Phase II as Topic,
pubmed-meshheading:16787142-Combined Modality Therapy,
pubmed-meshheading:16787142-Dexamethasone,
pubmed-meshheading:16787142-Drug Resistance, Neoplasm,
pubmed-meshheading:16787142-Estramustine,
pubmed-meshheading:16787142-Etoposide,
pubmed-meshheading:16787142-Gonadotropin-Releasing Hormone,
pubmed-meshheading:16787142-Growth Substances,
pubmed-meshheading:16787142-Humans,
pubmed-meshheading:16787142-Leuprolide,
pubmed-meshheading:16787142-Male,
pubmed-meshheading:16787142-Neoplasm Proteins,
pubmed-meshheading:16787142-Neoplasms, Hormone-Dependent,
pubmed-meshheading:16787142-Orchiectomy,
pubmed-meshheading:16787142-Osteoblasts,
pubmed-meshheading:16787142-Osteoclasts,
pubmed-meshheading:16787142-Paracrine Communication,
pubmed-meshheading:16787142-Peptides, Cyclic,
pubmed-meshheading:16787142-Prospective Studies,
pubmed-meshheading:16787142-Prostatic Neoplasms,
pubmed-meshheading:16787142-Randomized Controlled Trials as Topic,
pubmed-meshheading:16787142-Receptors, Androgen,
pubmed-meshheading:16787142-Salvage Therapy,
pubmed-meshheading:16787142-Somatostatin,
pubmed-meshheading:16787142-Survival Analysis,
pubmed-meshheading:16787142-Triptorelin Pamoate
|
|
pubmed:year |
2006
|
|
pubmed:articleTitle |
Combination therapy using LHRH and somatostatin analogues plus dexamethasone in androgen ablation refractory prostate cancer patients with bone involvement: a bench to bedside approach.
|
|
pubmed:affiliation |
University of Athens, Department of Basic Sciences, Medical School, 75 Micras Asias, Goudi-Athens 11527, Greece. mkouts@medscape.com
|
|
pubmed:publicationType |
Journal Article,
Comparative Study,
Review
|
